Patents by Inventor Kazuhiko Ohne
Kazuhiko Ohne has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9447090Abstract: An excellent drug for treating or preventing cardiovascular diseases, based on cGMP production enhancing action due to soluble guanylate cyclase activating action, is provided. It was found that imidazopyridine compounds having a carbamoyl group at the 3-position and a substituent bonded at the 8-position via an oxygen atom in an imidazo[1,2-a]pyridine skeleton exhibits a cGMP production enhancing action by a potent soluble guanylate cyclase activating action, and is useful as a drug for treating or preventing various soluble guanylate cyclase-related cardiovascular diseases, thereby completing the present invention.Type: GrantFiled: November 26, 2013Date of Patent: September 20, 2016Assignee: Astellas Pharma Inc.Inventors: Yuji Koga, Kyoichi Maeno, Ippei Sato, Yoshimasa Imamura, Takeshi Hanazawa, Maiko Iida, Kazuhiko Ohne, Kenichiro Imamura, Tsubasa Watanabe, Eisuke Nozawa, Hiroshi Shibata
-
Patent number: 9278968Abstract: [Problem] A pharmaceutical composition for treating or preventing various cardiovascular diseases, which have sGC activities based on improvement of cGMP signals, is provided. [Means for Solution] It was found that imidazo[1,2-a]pyridine compounds having a carbamoyl group at the 3-position and a particular cyclic group at the 8-position via a methyleneoxy group, or a salt thereof have sGC activation, and are useful as active ingredients of pharmaceutical compositions for treating or preventing various sGC-related cardiovascular diseases, in particular, peripheral arterial diseases, intermittent claudication, critical limb ischemia, hypertension, and pulmonary hypertension, thereby completing the present invention.Type: GrantFiled: November 28, 2013Date of Patent: March 8, 2016Assignee: Astellas Pharma Inc.Inventors: Toshio Kurosaki, Tsubasa Watanabe, Kazuhiko Ohne, Hiroki Ishioka, Eisuke Nozawa, Takeshi Hanazawa, Shunichiro Hachiya, Hiroshi Shibata, Yuji Koga, Ryo Mizoguchi
-
Patent number: 9199927Abstract: [Problem] Provided is a compound which is useful as an agent for preventing and/or treating renal diseases. [Means for Solution] The present inventors have conducted extensive studies on compounds having a trypsin inhibitory action, and as a result, they have found that a guanidinobenzoic acid compound has a trypsin inhibitory action, thereby completing the present invention. The guanidinobenzoic acid compound of the present invention can be used as an agent for preventing and/or treating renal disease as an agent which will substitute low-protein diet therapy, and an agent for preventing and/or treating trypsin-related diseases, for example, pancreatitis, gastroesophageal reflux disease, hepatic encephalopathy, influenza, and the like.Type: GrantFiled: September 14, 2012Date of Patent: December 1, 2015Assignee: Astellas Pharma Inc.Inventors: Jiro Fujiyasu, Kazuhiko Ohne, Susumu Yamaki, Tomoyoshi Imaizumi, Takeshi Hondo, Keisuke Matsuura, Tomohki Satou, Satoshi Sasamura
-
Publication number: 20150232464Abstract: [Problem] A pharmaceutical composition for treating or preventing various cardiovascular diseases, which have sGC activities based on improvement of cGMP signals, is provided. [Means for Solution] It was found that imidazo[1,2-a]pyridine compounds having a carbamoyl group at the 3-position and a particular cyclic group at the 8-position via a methyleneoxy group, or a salt thereof have sGC activation, and are useful as active ingredients of pharmaceutical compositions for treating or preventing various sGC-related cardiovascular diseases, in particular, peripheral arterial diseases, intermittent claudication, critical limb ischemia, hypertension, and pulmonary hypertension, thereby completing the present invention.Type: ApplicationFiled: November 28, 2013Publication date: August 20, 2015Applicant: ASTELLAS PHARMA INC.Inventors: Toshio Kurosaki, Tsubasa Watanabe, Kazuhiko Ohne, Hiroki Ishioka, Eisuke Nozawa, Takeshi Hanazawa, Shunichiro Hachiya, Hiroshi Shibata, Yuji Koga, Ryo Mizoguchi
-
Publication number: 20140378459Abstract: [Problem] Provided is a compound which is useful as an agent for preventing and/or treating renal diseases. [Means for Solution] The present inventors have conducted extensive studies on compounds having a trypsin inhibitory action, and as a result, they have found that a guanidinobenzoic acid compound has a trypsin inhibitory action, thereby completing the present invention. The guanidinobenzoic acid compound of the present invention can be used as an agent for preventing and/or treating renal disease as an agent which will substitute low-protein diet therapy, and an agent for preventing and/or treating trypsin-related diseases, for example, pancreatitis, gastroesophageal reflux disease, hepatic encephalopathy, influenza, and the like.Type: ApplicationFiled: September 14, 2012Publication date: December 25, 2014Applicant: ASTELLAS PHARMA INC.Inventors: Jiro Fujiyasu, Kazuhiko Ohne, Susumu Yamaki, Tomoyoshi Imaizumi, Takeshi Hondo, Keisuke Matsuura, Tomohki Satou, Satoshi Sasamura
-
Publication number: 20140088080Abstract: [Problem] An excellent drug for treating or preventing cardiovascular diseases, based on cGMP production enhancing action due to soluble guanylate cyclase activating action, is provided. [Means for Solution] It was found that imidazopyridine compounds having a carbamoyl group at the 3-position and a substituent bonded at the 8-position via an oxygen atom in an imidazo[1,2-a]pyridine skeleton exhibits a cGMP production enhancing action by a potent soluble guanylate cyclase activating action, and is useful as a drug for treating or preventing various soluble guanylate cyclase-related cardiovascular diseases, thereby completing the present invention.Type: ApplicationFiled: November 26, 2013Publication date: March 27, 2014Applicant: ASTELLAS PHARMA INC.Inventors: Yuji KOGA, Kyoichi MAENO, Ippei SATO, Yoshimasa IMAMURA, Takeshi HANAZAWA, Maiko IIDA, Kazuhiko OHNE, Kenichiro IMAMURA, Tsubasa WATANABE, Eisuke NOZAWA, Hiroshi SHIBATA
-
Patent number: 7459451Abstract: The invention relates to compound of the formula (I) or its salt, in which R1, R2, R3 and R4 are as defined in the description, their use of as medicament, the process for their preparation and use for the treatment of PDE-IV or TNF-? mediated diseases.Type: GrantFiled: July 1, 2005Date of Patent: December 2, 2008Assignee: Astellas Pharma Inc.Inventors: Yoshito Abe, Kazuhiko Ohne, Kentaro Sato, Makoto Inoue, Mitsuaki Okumura
-
Patent number: 7317009Abstract: The invention relates to compound of the formula (I) or its salt, in which R1, R2, R3 and R4 are as defined in the description, their use of as medicament, the process for their preparation and use for the treatment of PDE-IV or TNF-? mediated diseasesType: GrantFiled: August 8, 2006Date of Patent: January 8, 2008Assignee: Astellas Pharma Inc.Inventors: Yoshito Abe, Makoto Inoue, Tsuyoshi Mizutani, Kozo Sawada, Kazuhiko Ohne, Mitsuaki Okumura, Yuki Sawada, Kenichiro Imamura
-
Patent number: 7153854Abstract: The invention relates to compound of the formula (I) or its salt, in which R1, R2, R3 and R4 are as defined in the description, their use of as medicament, the process for their preparation and use for the treatment of PDE-IV or TNF-? mediated diseasesType: GrantFiled: December 30, 2003Date of Patent: December 26, 2006Assignee: Astellas Pharma Inc.Inventors: Yoshito Abe, Makoto Inoue, Tsuyoshi Mizutani, Kozo Sawada, Kazuhiko Ohne, Mitsuaki Okumura, Yuki Sawada, Kenichiro Imamura
-
Publication number: 20060270678Abstract: The invention relates to compound of the formula (I) or its salt, in which R1, R2, R3 and R4 are as defined in the description, their use of as medicament, the process for their preparation and use for the treatment of PDE-IV or TNF-? mediated diseases.Type: ApplicationFiled: August 8, 2006Publication date: November 30, 2006Applicant: Astellas Pharma Inc.Inventors: Yoshito Abe, Makoto Inoue, Tsuyoshi Mizutani, Kozo Sawada, Kazuhiko Ohne, Mitsuaki Okumura, Yuki Sawada, Kenichiro Imamura
-
Publication number: 20060004003Abstract: The invention relates to compound of the formula (I) or its salt, in which R1, R2, R3 and R4 are as defined in the description, their use of as medicament, the process for their preparation and use for the treatment of PDE-IV or TNF-? mediated diseases.Type: ApplicationFiled: July 1, 2005Publication date: January 5, 2006Applicant: Astellas Pharma Inc.Inventors: Yoshito Abe, Kazuhiko Ohne, Kentaro Sato, Makoto Inoue, Mitsuaki Okumura
-
Patent number: 6967197Abstract: A compound of formula (I) in which R1 is halo, lower alkoxy, optionally substituted aryl, optionally substituted aryloxy, optionally substituted heterecyclic group or optionally substituted lower alkynyl, R2 is amidated carboxy, R3 is hydrogen or acyl, Ar is aryl or heterocyclic group, X is thia, sulfinyl or sulfonyl, Y and Z are each lower alkylene, m and n are each an integer of 0 to 2, and a salt thereof, useful as inhibitors of matrix metalloproteinases (MMP) or the production of tumor necrosis factor ? (TNF ?)Type: GrantFiled: February 20, 2001Date of Patent: November 22, 2005Assignee: Fujisawa Pharmaceutical Co., Ltd.Inventors: Masahiro Neya, Hitoshi Yamazaki, Kazuhiko Ohne, Yuki Sawada, Tsuyoshi Mizutani, Yoshimasa Imamura, Noriko Mukai
-
Publication number: 20050075342Abstract: The invention relates to compound of the formula (I) or its salt, in which R1, R2, R3 and R4 are as defined in the description, their use of as medicament, the process for their preparation and use for the treatment of PDE-IV or TNF-? mediated diseases.Type: ApplicationFiled: December 30, 2003Publication date: April 7, 2005Applicant: FUJISAWA PHARMACEUTICAL CO., LTD.Inventors: Yoshito Abe, Makoto Inoue, Tsuyoshi Mizutani, Kozo Sawada, Kazuhiko Ohne, Mitsuaki Okumura, Yuki Sawada, Kenichiro Imamura
-
Publication number: 20040266826Abstract: A compound of the formula: in which R1 is optionally substituted phenyl, optionally substituted naphthyl, optionally substituted bicyclic heterocyclic group, optionally substituted lower alkenyl or optionally substituted lower alkynyl, and R2 is carboxy or protected carboxy, or a salt thereof, useful for treating and/or preventing MMP- or TNF-&agr; mediated diseases.Type: ApplicationFiled: February 27, 2004Publication date: December 30, 2004Inventors: Masahiro Neya, Akihiko Sawada, Kazuhiko Ohne, Yoshito Abe, Tsuyoshi Mizutani, Naoki Ishibashi, Makoto Inoue
-
Patent number: 6825200Abstract: The present invention a compound represented by the formula (I): where the structural variables R1-R6 are defined herein.Type: GrantFiled: May 6, 2002Date of Patent: November 30, 2004Assignee: Fujisawa Pharmaceutical Co., Ltd.Inventors: Ichiro Shima, Takehiko Ohkawa, Kazuhiko Ohne, Kentaro Sato, Naoki Ishibashi, Kenichiro Imamura
-
Publication number: 20030134849Abstract: A compound of formula (I) in which R1 is halo, lower alkoxy, optionally substituted aryl, optionally substituted aryloxy, optionally substituted heterecyclic group or optionally substituted lower alkynyl, R2 is amidated carboxy, R3 is hydrogen or acyl, Ar is aryl or heterocyclic group, X is thia, sulfinyl or sulfonyl, Y and Z are each lower alkylene, m and n are each an integer of 0 to 2, and a salt thereof, useful as inhibitors of matrix metalloproteinases (MMP) or the production of tumor necrosis factor &agr; (TNF &agr;).Type: ApplicationFiled: August 19, 2002Publication date: July 17, 2003Inventors: Masahiro Neya, Hitoshi Yamazaki, Kazuhiko Ohne, Yuki Sawada, Tsuyoshi Mizutani, Yoshimasa Imamura, Noriko Mukai
-
Publication number: 20020132809Abstract: 1Type: ApplicationFiled: February 25, 2002Publication date: September 19, 2002Applicant: Fujisawa Pharmaceutical Co. Ltd.Inventors: Teruo Oku, Ichiro Shima, Takehiko Ohkawa, Kazuhiko Ohne, Tatsuya Zenko, Kousei Yoshihara, Hiroyuki Setoi
-
Patent number: 6291464Abstract: This invention relates to new aminopiperazine derivatives having the potentiation of the cholinergic activity, etc., and represented by general formula [I]. wherein R1 is lower alkyl, etc., R2 is aryl, etc., A is or —SO2—, Q is —N═CH—, etc., X is lower alkylene, etc., and R3 and R4 are taken together to form lower alkylene, etc., and pharmaceutically acceptable salts thereof, to processes for preparation thereof and a pharmaceutical composition comprising the same.Type: GrantFiled: August 17, 1999Date of Patent: September 18, 2001Assignee: Fujisawa Pharmaceutical Co., Ltd.Inventors: Ichiro Shima, Kazuhiko Ohne
-
Patent number: 6069156Abstract: Compounds of the formula (I): ##STR1## and their pharmaceutically acceptable compositions are useful in inhibiting the activity of cyclic guanosine 3',5'-monophosphate phosphodiesterase.Type: GrantFiled: December 10, 1997Date of Patent: May 30, 2000Assignee: Fujisawa Pharmaceutical Co., Ltd.Inventors: Teruo Oku, Kozo Sawada, Akio Kuroda, Kazuhiko Ohne, Atsushi Nomoto, Naomi Hosogai, Yoshimitsu Nakajima, Akira Nagashima, Keizo Sogabe, Kouichi Tamura, Masakazu Kobayashi